Compile Data Set for Download or QSAR
maximum 50k data
Found 56 Enz. Inhib. hit(s) with all data for entry = 9780
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333120((S)-(3-(dimethylamino)azetidin-1-yl)(2-(6-(2-ethyl...)
Affinity DataKi:  0.0200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM431908(US10550118, Example 8-15 | US10954237, Example 8-1...)
Affinity DataKi:  0.0300nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333120((S)-(3-(dimethylamino)azetidin-1-yl)(2-(6-(2-ethyl...)
Affinity DataKi:  0.0400nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333145((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(5-et...)
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM431914(US10550118, Example 8-21 | US10954237, Example 8-2...)
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM431913(US10550118, Example 8-20 | US10954237, Example 8-2...)
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM431910(US10550118, Example 8-17 | US10954237, Example 8-1...)
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM488306(US10954237, Example 8-9)
Affinity DataKi:  0.0500nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM488298(US10954237, Example 8-1)
Affinity DataKi:  0.0600nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121((S)-(3-(dimethylamino)azetidin-1-yl)(2-(6-(2-ethyl...)
Affinity DataKi:  0.0600nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM431909(US10550118, Example 8-16 | US10947229, Example C-4...)
Affinity DataKi:  0.0600nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333144((S)-(3-(dimethylamino)azetidin-1-yl)(5-ethyl-2-(6-...)
Affinity DataKi:  0.0600nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM431906(US10550118, Example 8-13 | US10550118, Example 8-1...)
Affinity DataKi:  0.0600nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333120((S)-(3-(dimethylamino)azetidin-1-yl)(2-(6-(2-ethyl...)
Affinity DataKi:  0.0600nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM488303(US10954237, Example 8-6)
Affinity DataKi:  0.0600nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.0600nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333136((S)-(5-ethyl-2-(6-(2-ethyl-5-fluoro-4-hydroxypheny...)
Affinity DataKi:  0.0600nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM488300(US10954237, Example 8-3)
Affinity DataKi:  0.0600nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM488299(US10954237, Example 8-2)
Affinity DataKi:  0.0600nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333136((S)-(5-ethyl-2-(6-(2-ethyl-5-fluoro-4-hydroxypheny...)
Affinity DataKi:  0.0800nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333145((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(5-et...)
Affinity DataKi:  0.0800nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM488302(US10954237, Example 8-5)
Affinity DataKi:  0.0800nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333144((S)-(3-(dimethylamino)azetidin-1-yl)(5-ethyl-2-(6-...)
Affinity DataKi:  0.0800nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM431908(US10550118, Example 8-15 | US10954237, Example 8-1...)
Affinity DataKi:  0.0800nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM431909(US10550118, Example 8-16 | US10947229, Example C-4...)
Affinity DataKi:  0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM431911(US10550118, Example 8-18 | US10954237, Example 8-1...)
Affinity DataKi:  0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333120((S)-(3-(dimethylamino)azetidin-1-yl)(2-(6-(2-ethyl...)
Affinity DataKi:  0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM431906(US10550118, Example 8-13 | US10550118, Example 8-1...)
Affinity DataKi:  0.100nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121((S)-(3-(dimethylamino)azetidin-1-yl)(2-(6-(2-ethyl...)
Affinity DataKi:  0.130nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333136((S)-(5-ethyl-2-(6-(2-ethyl-5-fluoro-4-hydroxypheny...)
Affinity DataKi:  0.130nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM431910(US10550118, Example 8-17 | US10954237, Example 8-1...)
Affinity DataKi:  0.130nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM488306(US10954237, Example 8-9)
Affinity DataKi:  0.160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM488300(US10954237, Example 8-3)
Affinity DataKi:  0.160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(2-(6...)
Affinity DataKi:  0.160nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM488298(US10954237, Example 8-1)
Affinity DataKi:  0.180nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333136((S)-(5-ethyl-2-(6-(2-ethyl-5-fluoro-4-hydroxypheny...)
Affinity DataKi:  0.200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM431913(US10550118, Example 8-20 | US10954237, Example 8-2...)
Affinity DataKi:  0.200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM488302(US10954237, Example 8-5)
Affinity DataKi:  0.200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333145((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(5-et...)
Affinity DataKi:  0.200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM431906(US10550118, Example 8-13 | US10550118, Example 8-1...)
Affinity DataKi:  0.200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333120((S)-(3-(dimethylamino)azetidin-1-yl)(2-(6-(2-ethyl...)
Affinity DataKi:  0.200nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM431914(US10550118, Example 8-21 | US10954237, Example 8-2...)
Affinity DataKi:  0.25nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM431909(US10550118, Example 8-16 | US10947229, Example C-4...)
Affinity DataKi:  0.25nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM488303(US10954237, Example 8-6)
Affinity DataKi:  0.25nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM488299(US10954237, Example 8-2)
Affinity DataKi:  0.25nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333144((S)-(3-(dimethylamino)azetidin-1-yl)(5-ethyl-2-(6-...)
Affinity DataKi:  0.280nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333144((S)-(3-(dimethylamino)azetidin-1-yl)(5-ethyl-2-(6-...)
Affinity DataKi:  0.320nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333145((S)-(3-(dimethylamino)-3-methylazetidin-1-yl)(5-et...)
Affinity DataKi:  0.320nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM431909(US10550118, Example 8-16 | US10947229, Example C-4...)
Affinity DataKi:  0.320nMAssay Description:A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7.5, 0.01%...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 56 total ) | Next | Last >>
Jump to: